≡ MENU
Cell Therapies
Header5
Cell Therapies
Header4
Cell Therapies
Header1
Cell Therapies
Header2
Cell Therapies
Header3

Investors

FAQs

When was Cell Therapies established?

The Centre for Blood Cell Therapies, located at the Peter MacCallum Cancer Centre was initiated in 1999 and Cell Therapies P/L was established in 2003 to develop and manage the commercial interface for the Centre and related Peter Mac resources.

Who are its shareholders?

Peter MacCallum Cancer Centre is a 93% shareholder. The remaining shares are held by senior members of its executive team.

What facilities and resources?

Cell Therapies P/L  provides clients and collaborators with a regulatory-compliant, focused business unit, able to execute all aspects of contract manufacturing and the deployment of cellular products and services. We provide access to a wide range of services including apheresis, cryopreservation, advanced imaging for in vivo cell tracking, clinical trial design and approval, and clinical trial design.

Who are our clients?

  • Organisations requiring TGA/EMA/FDA compliant manufacturing in order to undertake Phase I through III clinical trials
  • Organisations requiring access to Australian, New Zealand and Asian┬ácountries for their cell based products
  • Organisations requiring cellular therapy process development to achieve commercially viable scalable products

What investment opportunities are available?

Cell Therapies P/L is evolving with the emergence of cellular therapy as a commercially viable new paradigm for regenerative medicine and immunotherapy.

To capture the opportunities at hand and expected in the near future, Cell Therapies P/L may require expansion capital and additional strategic alliance partners. Please contact us to explore opportunities.